alpha-Synuclein Antibody (2A7)

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-05194

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human, Mouse, Rat, Porcine, Bovine

Cited:

Human, Mouse

Applications

Validated:

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry Free-Floating, Simple Western, Western Blot

Cited:

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 2A7

Concentration

1 mg/ml

View all alpha-Synuclein Antibodies »

Product Specifications

Immunogen

This alpha-Synuclein Antibody (2A7) was developed against full length human recombinant protein with the epitope from amino acids 61-95.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

15 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for alpha-Synuclein Antibody (2A7)

Immunohistochemistry Free-Floating: alpha-Synuclein Antibody (2A7) [NBP1-05194]

Immunohistochemistry Free-Floating: alpha-Synuclein Antibody (2A7) [NBP1-05194]

Immunohistochemistry Free-Floating: alpha-Synuclein Antibody (2A7) [NBP1-05194] - Analysis of rat cerebellum section costained with mouse mAb to alpha-synuclein NBP1-05194, dilution 1:1,000, in red, and rabbit pAb to GFAP, dilution 1:5,000 in green. The blue is DAPI staining of nuclear DNA. Following transcardial perfusion of rat with 4% paraformaldehyde, brain was post fixed for 24 hours, cut to 45uM, and free-floating sections were stained with above antibodies. The alpha-synuclein protein is concentrated in synaptic regions, while the GFAP antibody stains the filamentous cytoskeleton of Bergmann glia and astrocytic cells.
Simple Western: alpha-Synuclein Antibody (2A7) [NBP1-05194]

Simple Western: alpha-Synuclein Antibody (2A7) [NBP1-05194]

Simple Western: alpha-Synuclein Antibody (2A7) [NBP1-05194] - Synuclein-alpha Antibody (2A7) [NBP1-05194] - Simple Western lane view shows a specific band for alpha-Synuclein in 0.05 mg/ml of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.
Western Blot: alpha-Synuclein Antibody (2A7) [NBP1-05194]

Western Blot: alpha-Synuclein Antibody (2A7) [NBP1-05194]

Western Blot: alpha-Synuclein Antibody (2A7) [NBP1-05194] - Western blot analysis of tissue lysates using mAb to alpha-synuclein NBP1-05194. dilution 1:1,000 in green. Lane [1] protein standard in red, [2] whole rat brain lysate, [3] rat spinal cord lysate. Strong band at about 15kDa corresponds to alpha-synuclein protein.
View 2 more images

Applications for alpha-Synuclein Antibody (2A7)

Application
Recommended Usage

Flow Cytometry

2-5ug/0.1x10^6 cells

Immunocytochemistry/ Immunofluorescence

1:1000

Immunohistochemistry

1:1000

Immunohistochemistry Free-Floating

1:1000

Simple Western

1:2000

Western Blot

1:1000
Application Notes
This alpha-Synuclein antibody is useful for Immunocytochemistry/Immunofluorescence and Western Blot.

In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. Separated by Size-Wes, Sally Sue/Peggy Sue.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

50% PBS, 50% glycerol

Preservative

0.035% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: alpha-Synuclein

Alpha-synuclein, a member of the synuclein family, is a protein that was first identified in 1988 whose name is derived from its localization to both the synapse and nucleus (1-3). Specifically, it is expressed primarily in the brain, including Lewy Bodies (1-6). Alpha-synuclein is encoded by the SNCA gene, located on chromosome 4p21, and is processed as a 140 amino acid (aa) protein with a theoretical molecular weight of 14 kDa (1,2,4). Structurally alpha-synuclein consists of a N-terminal binding domain (1-60 aa), a central domain core region called the non-amyloid-beta component (NAC) (61-95 aa), and a C-terminal domain (96-140 aa) (1-3). The N-terminal region contains aa repeats with a KTKEGV consensus sequence that gives the protein its alpha-helical structure that associates with lipid membranes (1-4). The hydrophobic NAC region is responsible for alpha-synuclein aggregation and fibril formation (1-4). The acidic C-terminal tail is largely unstructured but can be targeted for post-translational modifications (1-4). The function of alpha-synuclein is not entirely understood, but it is shown to have a role in suppression of apoptosis, acting as a molecular chaperone, regulating glucose, and modulating calmodulin activity (1,3).

A number of studies have revealed that alpha-synuclein aggregation is a hallmark feature in a number of neurodegenerative diseases, referred to as synucleinopathies (2-4). Alpha-synuclein protein aggregates are a large component of Lewy bodies that are present in Parkinson's disease (PD), Lewy body dementia (LBD), and multiple system atrophy (1-6). Research has shown phosphorylation of alpha-synuclein at Ser129 moves the protein from the nucleus to the cytoplasm and promotes fibril formation associated with synucleinopathies (1,2,5). Recent studies also suggest that alpha-synuclein accumulation can prevent mitochondrial import machinery causing mitochondrial dysfunction that is often observed in neurodegeneration (5). It is thought that preventing alpha-synuclein aggregation may prevent PD, thus alpha-synuclein is a target for many potential therapeutic interventions aimed at decreasing aggregate formation or increasing clearance (1,2,4-6).

References

1. Villar-Pique, A., Lopes da Fonseca, T., & Outeiro, T. F. (2016). Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. Journal of neurochemistry. https://doi.org/10.1111/jnc.13249

2. Emamzadeh F. N. (2016). Alpha-synuclein structure, functions, and interactions. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. https://doi.org/10.4103/1735-1995.181989

3. Burre J. (2015). The Synaptic Function of alpha-Synuclein. Journal of Parkinson's disease. https://doi.org/10.3233/JPD-150642

4. Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013). The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nature reviews. Neuroscience. https://doi.org/10.1038/nrn3406

5. Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018). Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Neurobiology of disease. https://doi.org/10.1016/j.nbd.2017.04.004

6. O'Leary, E. I., & Lee, J. C. (2019). Interplay between alpha-synuclein amyloid formation and membrane structure. Biochimica et biophysica acta. Proteins and proteomics. https://doi.org/10.1016/j.bbapap.2018.09.012

Alternate Names

NACP, PARK1, PARK4, SNCA, Synuclein-alpha

Entrez Gene IDs

6622 (Human); 20617 (Mouse)

Gene Symbol

SNCA

UniProt

P37840

Additional alpha-Synuclein Products

Product Documents for alpha-Synuclein Antibody (2A7)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for alpha-Synuclein Antibody (2A7)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.